Jean-Charles Soria, SVP and Oncology Therapeutic Area Head of Amgen, shared an article by Zachary C. Hartman et al. on X:

“ADC’s Bystander Effect may be crucial for efficacy!

In a provocative recent paper, HER2 ADC’s payload may not need ADC internalization for efficacy !

Activity may rely on extracellular proteases, such as cathepsin L (CTSL). This extracellular release in the TME appears to kill nearby HER2-low/negative cancer cells.”

Title: Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)

Authors: Li-Chung Tsao, Zachary C. Hartman, et al.

Journal: Nature Communications, April 2025

Jean-Charles Soria: ADC’s Bystander Effect may be crucial for efficacy

More posts featuring Jean-Charles Soria.